Share Price and Basic Stock Data
Last Updated: January 7, 2026, 11:08 pm
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Krebs Biochemicals & Industries Ltd operates in the pharmaceuticals sector, with a current market capitalization of ₹149 Cr and a share price of ₹68.0. The company has exhibited fluctuating revenue trends over recent quarters. For instance, sales peaked at ₹20.94 Cr in September 2022 but saw a significant decline to ₹9.09 Cr by December 2022. The most recent quarter, September 2023, reported sales of ₹14.89 Cr, indicating a recovery from earlier lows, although still below the previous peak. Annual sales figures reflect a similar trend, with ₹52 Cr in March 2023, down from ₹60 Cr in March 2022, and projected to decline further to ₹43 Cr in March 2025. This declining sales trajectory raises concerns about the company’s ability to regain previous revenue levels. The overall sales performance remains volatile, which may challenge investor confidence moving forward.
Profitability and Efficiency Metrics
Krebs Biochemicals has faced ongoing challenges in profitability, with a recorded net profit of -₹27 Cr for the latest fiscal year ending March 2025. The operating profit margin (OPM) has been consistently negative, with -67.15% reported in September 2025, indicating substantial operational inefficiencies. The company’s interest coverage ratio stood at -2.42x, suggesting that it is unable to cover its interest obligations from operating profits. This is compounded by a cash conversion cycle that has deteriorated to -795 days, highlighting severe liquidity issues. The return on equity (ROE) percentage is absent, which typically signifies a lack of profitability relative to shareholders’ equity. Overall, the financial metrics indicate a concerning profitability landscape, calling for urgent operational and strategic adjustments to improve efficiency and financial health.
Balance Sheet Strength and Financial Ratios
The balance sheet of Krebs Biochemicals reflects significant financial strain, with total borrowings amounting to ₹219 Cr against negative reserves of ₹179 Cr. This indicates that the company may be heavily reliant on debt to finance its operations. The debt-to-equity ratio is notably high at -0.56x, which signifies that the company has more liabilities than equity. Additionally, the current ratio is alarmingly low at 0.09, suggesting potential liquidity issues and an inability to meet short-term obligations. The book value per share is reported at -₹67.83, reinforcing the notion of negative equity. Furthermore, the company’s enterprise value (EV) stands at ₹356.07 Cr, while its EV to net operating revenue ratio is 8.22, indicating that the market is valuing the company significantly higher than its revenue generation capacity. These factors collectively point to a precarious financial position that warrants close scrutiny from potential investors.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Krebs Biochemicals reveals a dominant promoter stake of 72.74%, which may provide some stability in governance. However, foreign institutional investors (FIIs) hold a mere 0.50%, suggesting limited external investment interest. The public shareholding stands at 26.76%, reflecting a relatively small investor base of 8,912 shareholders. This low level of institutional investment might indicate a lack of confidence in the company’s financial health and growth prospects. Over recent quarters, the number of shareholders has fluctuated, with a notable decline to 8,798 by March 2025 from a peak of 9,315 in March 2023. Such trends could imply waning investor interest, which may further complicate the company’s capital-raising efforts in the future. The high promoter holding coupled with low public and institutional participation may create a lack of market liquidity, impacting share price performance.
Outlook, Risks, and Final Insight
The outlook for Krebs Biochemicals appears challenging, characterized by declining revenues, persistent operational losses, and significant leverage. The primary risks include the company’s inability to generate consistent sales growth, high dependency on debt, and deteriorating liquidity ratios, which could hinder its operational viability. Additionally, the negative equity and low institutional investment raise concerns about long-term sustainability. Conversely, the high promoter stake may provide a degree of stability and potential for strategic restructuring. If the company can implement effective operational improvements and enhance its revenue-generating capacity, there is a possibility for recovery. However, without decisive action to address these financial deficiencies, Krebs Biochemicals may continue to struggle in a competitive pharmaceutical landscape, limiting its growth prospects and investor appeal.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 126 Cr. | 100 | 214/84.3 | 27.9 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.29/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,631 Cr. | 424 | 479/192 | 95.9 | 24.3 | 0.16 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 34.5 Cr. | 46.5 | 87.8/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 58.1 Cr. | 39.7 | 40.0/17.0 | 138 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,857.51 Cr | 1,159.04 | 54.42 | 202.18 | 0.35% | 16.29% | 15.20% | 6.10 |
All Competitor Stocks of Krebs Biochemicals & Industries Ltd
Quarterly Result
| Metric | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 20.94 | 9.09 | 11.46 | 10.58 | 14.89 | 12.98 | 11.97 | 12.89 | 12.86 | 11.47 | 6.10 | 5.48 | 4.17 |
| Expenses | 22.84 | 12.07 | 16.08 | 13.20 | 15.79 | 15.07 | 15.09 | 15.08 | 15.58 | 16.18 | 11.51 | 7.57 | 6.97 |
| Operating Profit | -1.90 | -2.98 | -4.62 | -2.62 | -0.90 | -2.09 | -3.12 | -2.19 | -2.72 | -4.71 | -5.41 | -2.09 | -2.80 |
| OPM % | -9.07% | -32.78% | -40.31% | -24.76% | -6.04% | -16.10% | -26.07% | -16.99% | -21.15% | -41.06% | -88.69% | -38.14% | -67.15% |
| Other Income | 0.27 | 0.02 | 0.19 | 0.04 | 0.17 | 0.03 | 0.21 | 0.03 | 0.09 | 0.25 | 0.34 | 0.01 | 0.01 |
| Interest | 0.74 | 0.90 | 1.03 | 1.10 | 1.13 | 1.19 | 1.27 | 1.32 | 1.42 | 1.56 | 1.61 | 1.65 | 1.73 |
| Depreciation | 1.69 | 1.69 | 1.48 | 1.65 | 1.71 | 1.73 | 1.67 | 1.69 | 1.71 | 1.72 | 1.57 | 1.60 | 1.62 |
| Profit before tax | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.25 | -5.33 | -6.14 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.24% | 0.00% | 0.00% |
| Net Profit | -4.06 | -5.55 | -6.94 | -5.33 | -3.57 | -4.98 | -5.85 | -5.17 | -5.76 | -7.74 | -8.27 | -5.32 | -6.14 |
| EPS in Rs | -1.88 | -2.57 | -3.22 | -2.47 | -1.66 | -2.31 | -2.71 | -2.40 | -2.67 | -3.59 | -3.84 | -2.47 | -2.85 |
Last Updated: December 30, 2025, 5:32 am
Below is a detailed analysis of the quarterly data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Sales, as of Sep 2025, the value is 4.17 Cr.. The value appears to be declining and may need further review. It has decreased from 5.48 Cr. (Jun 2025) to 4.17 Cr., marking a decrease of 1.31 Cr..
- For Expenses, as of Sep 2025, the value is 6.97 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 7.57 Cr. (Jun 2025) to 6.97 Cr., marking a decrease of 0.60 Cr..
- For Operating Profit, as of Sep 2025, the value is -2.80 Cr.. The value appears to be declining and may need further review. It has decreased from -2.09 Cr. (Jun 2025) to -2.80 Cr., marking a decrease of 0.71 Cr..
- For OPM %, as of Sep 2025, the value is -67.15%. The value appears to be declining and may need further review. It has decreased from -38.14% (Jun 2025) to -67.15%, marking a decrease of 29.01%.
- For Other Income, as of Sep 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.01 Cr..
- For Interest, as of Sep 2025, the value is 1.73 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.65 Cr. (Jun 2025) to 1.73 Cr., marking an increase of 0.08 Cr..
- For Depreciation, as of Sep 2025, the value is 1.62 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.60 Cr. (Jun 2025) to 1.62 Cr., marking an increase of 0.02 Cr..
- For Profit before tax, as of Sep 2025, the value is -6.14 Cr.. The value appears to be declining and may need further review. It has decreased from -5.33 Cr. (Jun 2025) to -6.14 Cr., marking a decrease of 0.81 Cr..
- For Tax %, as of Sep 2025, the value is 0.00%. The value remains steady. There is no change compared to the previous period (Jun 2025) which recorded 0.00%.
- For Net Profit, as of Sep 2025, the value is -6.14 Cr.. The value appears to be declining and may need further review. It has decreased from -5.32 Cr. (Jun 2025) to -6.14 Cr., marking a decrease of 0.82 Cr..
- For EPS in Rs, as of Sep 2025, the value is -2.85. The value appears to be declining and may need further review. It has decreased from -2.47 (Jun 2025) to -2.85, marking a decrease of 0.38.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: December 15, 2025, 5:04 am
| Metric | Sep 2014n n 15m | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | -0 | -0 | 1 | 3 | 34 | 48 | 33 | 54 | 60 | 52 | 50 | 43 | 27 |
| Expenses | 4 | 5 | 14 | 11 | 41 | 58 | 52 | 71 | 94 | 68 | 59 | 58 | 42 |
| Operating Profit | -4 | -5 | -12 | -8 | -8 | -10 | -19 | -18 | -34 | -16 | -9 | -15 | -15 |
| OPM % | -1,088% | -248% | -22% | -20% | -56% | -33% | -57% | -30% | -17% | -35% | -55% | ||
| Other Income | 0 | 3 | 1 | -0 | -1 | 0 | 0 | 1 | 1 | 1 | 0 | 1 | 1 |
| Interest | 0 | 4 | 1 | 3 | 5 | 6 | 6 | 6 | 5 | 3 | 5 | 6 | 7 |
| Depreciation | -0 | 2 | 4 | 4 | 4 | 4 | 5 | 5 | 6 | 7 | 7 | 7 | 7 |
| Profit before tax | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| Tax % | 10% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | 0% | |
| Net Profit | -4 | -8 | -16 | -16 | -18 | -20 | -29 | -28 | -45 | -25 | -20 | -27 | -27 |
| EPS in Rs | -3.78 | -6.82 | -10.33 | -9.67 | -10.73 | -12.03 | -16.04 | -14.45 | -20.65 | -11.45 | -9.15 | -12.50 | -12.75 |
| Dividend Payout % | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% | -0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 0.00% | -12.50% | -11.11% | -45.00% | 3.45% | -60.71% | 44.44% | 20.00% | -35.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -12.50% | 1.39% | -33.89% | 48.45% | -64.16% | 105.16% | -24.44% | -55.00% |
Krebs Biochemicals & Industries Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 5% |
| 3 Years: | -10% |
| TTM: | -32% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | 1% |
| 3 Years: | 12% |
| TTM: | -38% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -1% |
| 5 Years: | -4% |
| 3 Years: | -19% |
| 1 Year: | -15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | % |
Last Updated: September 5, 2025, 9:20 am
Balance Sheet
Last Updated: December 10, 2025, 2:59 am
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 10 | 10 | 13 | 14 | 14 | 17 | 18 | 20 | 22 | 22 | 22 | 22 | 22 |
| Reserves | -6 | 9 | -0 | -12 | -32 | -31 | -43 | -62 | -97 | -121 | -141 | -168 | -179 |
| Borrowings | 93 | 61 | 31 | 48 | 56 | 53 | 66 | 111 | 143 | 183 | 194 | 212 | 219 |
| Other Liabilities | 41 | 29 | 73 | 73 | 87 | 103 | 93 | 91 | 122 | 91 | 104 | 103 | 106 |
| Total Liabilities | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 168 |
| Fixed Assets | 58 | 58 | 93 | 102 | 101 | 101 | 105 | 118 | 139 | 147 | 150 | 146 | 146 |
| CWIP | 0 | 0 | 11 | 4 | 4 | 3 | 4 | 12 | 8 | 4 | 2 | 3 | 1 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 80 | 50 | 13 | 16 | 21 | 38 | 24 | 29 | 43 | 24 | 26 | 20 | 20 |
| Total Assets | 138 | 108 | 116 | 122 | 126 | 142 | 134 | 159 | 190 | 175 | 178 | 169 | 168 |
Below is a detailed analysis of the balance sheet data for Krebs Biochemicals & Industries Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 22.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 22.00 Cr..
- For Reserves, as of Sep 2025, the value is -179.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -168.00 Cr. (Mar 2025) to -179.00 Cr., marking a decline of 11.00 Cr..
- For Borrowings, as of Sep 2025, the value is 219.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 212.00 Cr. (Mar 2025) to 219.00 Cr., marking an increase of 7.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 106.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 103.00 Cr. (Mar 2025) to 106.00 Cr., marking an increase of 3.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 168.00 Cr.. The value appears to be improving (decreasing). It has decreased from 169.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 1.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 146.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 146.00 Cr..
- For CWIP, as of Sep 2025, the value is 1.00 Cr.. The value appears to be declining and may need further review. It has decreased from 3.00 Cr. (Mar 2025) to 1.00 Cr., marking a decrease of 2.00 Cr..
- For Investments, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Other Assets, as of Sep 2025, the value is 20.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 20.00 Cr..
- For Total Assets, as of Sep 2025, the value is 168.00 Cr.. The value appears to be declining and may need further review. It has decreased from 169.00 Cr. (Mar 2025) to 168.00 Cr., marking a decrease of 1.00 Cr..
However, the Borrowings (219.00 Cr.) are higher than the Reserves (-179.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2014n n 15m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -5.00 | -43.00 | -56.00 | -64.00 | -63.00 | -85.00 | -129.00 | -177.00 | -199.00 | -203.00 | -227.00 | -4.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 10 | 180 | 3 | 22 | 2 | 2 | 5 | 4 | 14 | 0 | ||
| Inventory Days | 14,704 | 2,162 | 337 | 142 | 345 | 234 | 230 | 170 | 543 | 396 | ||
| Days Payable | 32,250 | 4,360 | 510 | 339 | 521 | 292 | 340 | 217 | 1,051 | 1,192 | ||
| Cash Conversion Cycle | -17,536 | -2,018 | -170 | -175 | -174 | -57 | -106 | -44 | -494 | -795 | ||
| Working Capital Days | -6,532 | -2,132 | -275 | -315 | -267 | -187 | -261 | -232 | -322 | -787 | ||
| ROCE % | -4% | -8% | -26% | -26% | -26% | -36% | -57% | -40% | -57% | -29% | -19% | -30% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Diluted EPS (Rs.) | -12.49 | -9.16 | -11.30 | -20.81 | -14.53 |
| Cash EPS (Rs.) | -9.39 | -6.01 | -8.41 | -17.73 | -11.84 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -67.83 | -55.29 | -46.13 | -34.83 | -21.78 |
| Revenue From Operations / Share (Rs.) | 20.09 | 23.39 | 24.18 | 27.69 | 27.37 |
| PBDIT / Share (Rs.) | -6.64 | -3.84 | -7.03 | -15.23 | -8.64 |
| PBIT / Share (Rs.) | -9.74 | -6.97 | -10.07 | -18.15 | -11.25 |
| PBT / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| Net Profit / Share (Rs.) | -12.49 | -9.15 | -11.45 | -20.65 | -14.45 |
| PBDIT Margin (%) | -33.06 | -16.40 | -29.07 | -55.00 | -31.57 |
| PBIT Margin (%) | -48.50 | -29.82 | -41.65 | -65.55 | -41.11 |
| PBT Margin (%) | -62.16 | -39.12 | -47.36 | -74.58 | -52.80 |
| Net Profit Margin (%) | -62.19 | -39.12 | -47.36 | -74.58 | -52.80 |
| Return on Capital Employeed (%) | -32.07 | -12.92 | -17.25 | -35.02 | -19.88 |
| Return On Assets (%) | -15.93 | -11.07 | -14.11 | -23.45 | -17.81 |
| Long Term Debt / Equity (X) | -0.21 | -0.44 | -0.43 | -0.03 | -2.35 |
| Total Debt / Equity (X) | -0.56 | -0.53 | -0.53 | -0.17 | -2.35 |
| Asset Turnover Ratio (%) | 0.24 | 0.28 | 0.28 | 0.34 | 0.36 |
| Current Ratio (X) | 0.09 | 0.28 | 0.32 | 0.45 | 0.44 |
| Quick Ratio (X) | 0.04 | 0.12 | 0.08 | 0.12 | 0.09 |
| Inventory Turnover Ratio (X) | 5.47 | 0.49 | 0.81 | 2.19 | 1.62 |
| Interest Coverage Ratio (X) | -2.42 | -1.76 | -5.10 | -6.09 | -2.70 |
| Interest Coverage Ratio (Post Tax) (X) | -3.56 | -3.21 | -7.30 | -7.26 | -3.52 |
| Enterprise Value (Cr.) | 356.07 | 324.85 | 304.75 | 451.99 | 274.16 |
| EV / Net Operating Revenue (X) | 8.22 | 6.44 | 5.85 | 7.57 | 5.11 |
| EV / EBITDA (X) | -24.86 | -39.27 | -20.10 | -13.76 | -16.17 |
| MarketCap / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| Price / BV (X) | -0.98 | -1.10 | -1.22 | -4.12 | -4.08 |
| Price / Net Operating Revenue (X) | 3.32 | 2.61 | 2.33 | 5.18 | 3.25 |
| EarningsYield | -0.18 | -0.14 | -0.20 | -0.14 | -0.16 |
After reviewing the key financial ratios for Krebs Biochemicals & Industries Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Diluted EPS (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 5. It has decreased from -9.16 (Mar 24) to -12.49, marking a decrease of 3.33.
- For Cash EPS (Rs.), as of Mar 25, the value is -9.39. This value is below the healthy minimum of 3. It has decreased from -6.01 (Mar 24) to -9.39, marking a decrease of 3.38.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -67.83. It has decreased from -55.29 (Mar 24) to -67.83, marking a decrease of 12.54.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 20.09. It has decreased from 23.39 (Mar 24) to 20.09, marking a decrease of 3.30.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -6.64. This value is below the healthy minimum of 2. It has decreased from -3.84 (Mar 24) to -6.64, marking a decrease of 2.80.
- For PBIT / Share (Rs.), as of Mar 25, the value is -9.74. This value is below the healthy minimum of 0. It has decreased from -6.97 (Mar 24) to -9.74, marking a decrease of 2.77.
- For PBT / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 0. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -12.49. This value is below the healthy minimum of 2. It has decreased from -9.15 (Mar 24) to -12.49, marking a decrease of 3.34.
- For PBDIT Margin (%), as of Mar 25, the value is -33.06. This value is below the healthy minimum of 10. It has decreased from -16.40 (Mar 24) to -33.06, marking a decrease of 16.66.
- For PBIT Margin (%), as of Mar 25, the value is -48.50. This value is below the healthy minimum of 10. It has decreased from -29.82 (Mar 24) to -48.50, marking a decrease of 18.68.
- For PBT Margin (%), as of Mar 25, the value is -62.16. This value is below the healthy minimum of 10. It has decreased from -39.12 (Mar 24) to -62.16, marking a decrease of 23.04.
- For Net Profit Margin (%), as of Mar 25, the value is -62.19. This value is below the healthy minimum of 5. It has decreased from -39.12 (Mar 24) to -62.19, marking a decrease of 23.07.
- For Return on Capital Employeed (%), as of Mar 25, the value is -32.07. This value is below the healthy minimum of 10. It has decreased from -12.92 (Mar 24) to -32.07, marking a decrease of 19.15.
- For Return On Assets (%), as of Mar 25, the value is -15.93. This value is below the healthy minimum of 5. It has decreased from -11.07 (Mar 24) to -15.93, marking a decrease of 4.86.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -0.21. This value is below the healthy minimum of 0.2. It has increased from -0.44 (Mar 24) to -0.21, marking an increase of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is -0.56. This value is within the healthy range. It has decreased from -0.53 (Mar 24) to -0.56, marking a decrease of 0.03.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.24. It has decreased from 0.28 (Mar 24) to 0.24, marking a decrease of 0.04.
- For Current Ratio (X), as of Mar 25, the value is 0.09. This value is below the healthy minimum of 1.5. It has decreased from 0.28 (Mar 24) to 0.09, marking a decrease of 0.19.
- For Quick Ratio (X), as of Mar 25, the value is 0.04. This value is below the healthy minimum of 1. It has decreased from 0.12 (Mar 24) to 0.04, marking a decrease of 0.08.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 5.47. This value is within the healthy range. It has increased from 0.49 (Mar 24) to 5.47, marking an increase of 4.98.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.42. This value is below the healthy minimum of 3. It has decreased from -1.76 (Mar 24) to -2.42, marking a decrease of 0.66.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -3.56. This value is below the healthy minimum of 3. It has decreased from -3.21 (Mar 24) to -3.56, marking a decrease of 0.35.
- For Enterprise Value (Cr.), as of Mar 25, the value is 356.07. It has increased from 324.85 (Mar 24) to 356.07, marking an increase of 31.22.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 8.22. This value exceeds the healthy maximum of 3. It has increased from 6.44 (Mar 24) to 8.22, marking an increase of 1.78.
- For EV / EBITDA (X), as of Mar 25, the value is -24.86. This value is below the healthy minimum of 5. It has increased from -39.27 (Mar 24) to -24.86, marking an increase of 14.41.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For Price / BV (X), as of Mar 25, the value is -0.98. This value is below the healthy minimum of 1. It has increased from -1.10 (Mar 24) to -0.98, marking an increase of 0.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 3.32. This value exceeds the healthy maximum of 3. It has increased from 2.61 (Mar 24) to 3.32, marking an increase of 0.71.
- For EarningsYield, as of Mar 25, the value is -0.18. This value is below the healthy minimum of 5. It has decreased from -0.14 (Mar 24) to -0.18, marking a decrease of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Krebs Biochemicals & Industries Ltd:
- Net Profit Margin: -62.19%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -32.07% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -3.56
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.04
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 54.42)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -0.56
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -62.19%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | Kothapalli Village, Kasimkota Mandal, Anakapalli Dist. Andhra Pradesh 531031 | Contact not found |
| Management | |
|---|---|
| Name | Position Held |
| Dr. R T Ravi | Chairman & Non-Exe.Director |
| Mr. Manish Kumar Jain | Managing Director & CEO |
| Mr. P K Bhattacharyya | Non Executive Director |
| Mr. Avinash Ravi | Non Executive Director |
| Mr. P M Kathariya | Independent Director |
| Ms. Dipti Shah | Independent Director |
| Mr. Satya Prakash Chigurupati | Independent Director |
| Mr. Sumanth Karlapudi | Independent Director |
FAQ
What is the intrinsic value of Krebs Biochemicals & Industries Ltd?
Krebs Biochemicals & Industries Ltd's intrinsic value (as of 08 January 2026) is ₹134.40 which is 97.65% higher the current market price of ₹68.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's ₹149 Cr. market cap, FY2025-2026 high/low of ₹114/63.6, reserves of ₹-179 Cr, and liabilities of ₹168 Cr.
What is the Market Cap of Krebs Biochemicals & Industries Ltd?
The Market Cap of Krebs Biochemicals & Industries Ltd is 149 Cr..
What is the current Stock Price of Krebs Biochemicals & Industries Ltd as on 08 January 2026?
The current stock price of Krebs Biochemicals & Industries Ltd as on 08 January 2026 is ₹68.0.
What is the High / Low of Krebs Biochemicals & Industries Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Krebs Biochemicals & Industries Ltd stocks is ₹114/63.6.
What is the Stock P/E of Krebs Biochemicals & Industries Ltd?
The Stock P/E of Krebs Biochemicals & Industries Ltd is .
What is the Book Value of Krebs Biochemicals & Industries Ltd?
The Book Value of Krebs Biochemicals & Industries Ltd is 73.2.
What is the Dividend Yield of Krebs Biochemicals & Industries Ltd?
The Dividend Yield of Krebs Biochemicals & Industries Ltd is 0.00 %.
What is the ROCE of Krebs Biochemicals & Industries Ltd?
The ROCE of Krebs Biochemicals & Industries Ltd is 30.1 %.
What is the ROE of Krebs Biochemicals & Industries Ltd?
The ROE of Krebs Biochemicals & Industries Ltd is %.
What is the Face Value of Krebs Biochemicals & Industries Ltd?
The Face Value of Krebs Biochemicals & Industries Ltd is 10.0.